Clinical Trial ResultsCDI-988 yields favorable Phase 1 results with no serious adverse events or treatment-emergent adverse events reported.
Drug Development ProgressCDI-988 has completed the single ascending dose stage of the Phase 1 trial for its oral protease inhibitor in development for norovirus and coronavirus, with safety and tolerability considered sufficient to continue to the next stage.
Vaccine EfficacyStudies of influenza drug CC-42344 have shown efficacy against the new avian influenza strain H5N1, making it an effective vaccine.